InsidersTradesSigma
Follow the STRYKER CORP stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, STRYKER CORP has logged 351 insider filings. Market capitalisation: €126.8bn. The latest transaction was disclosed on 26 August 2026 (Cession). Among the most active insiders: STRYKER RONDA E. All data is accessible without an account.
351
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€256m
97 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate STRYKER CORP Buy (bullish), based on 25 analysts. Average price target: US$382.72.
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 12,255 of 29,062 companies
56.0
score / 100
Value42
Quality70
FCF yld3.4%
Earn yld2.6%
EV/EBITDA22.2x
ROE17%
Gross mgn64%
Net mgn13%
Debt/EBITDA2.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 26 August 2026
Declarations351 total
441 shares@ US$328.605Common StockSEC:0002104636-26-000005:0
80 shares@ US$335.0550.0000% mcap0.0% of flowCommon StockSEC:0001242914-26-000010:11
16,612 shares@ US$340.7060.0045% mcap2.1% of flowCommon StockSEC:0001242914-26-000010:16
2,308 shares@ US$337.9820.0006% mcap0.3% of flowCommon StockSEC:0001242914-26-000010:13
3,852 shares@ US$342.7970.0011% mcap0.5% of flowCommon StockSEC:0001242914-26-000010:18
2,239 shares@ US$331.7420.0006% mcap0.3% of flowCommon StockSEC:0001242914-26-000010:0
2,920 shares@ US$332.6940.0008% mcap0.4% of flowCommon StockSEC:0001242914-26-000010:1
8,404 shares@ US$333.8250.0023% mcap1.0% of flowCommon StockSEC:0001242914-26-000010:2
25,536 shares@ US$334.9450.0069% mcap3.2% of flowCommon StockSEC:0001242914-26-000010:3
131,752 shares@ US$335.6420.036% mcap16.4% of flowCommon StockSEC:0001242914-26-000010:4
109,425 shares@ US$336.4330.030% mcap13.7% of flowCommon StockSEC:0001242914-26-000010:5
16,243 shares@ US$337.6290.0044% mcap2.0% of flowCommon StockSEC:0001242914-26-000010:6
3,481 shares@ US$338.4980.0009% mcap0.4% of flowCommon StockSEC:0001242914-26-000010:7
40 shares@ US$331.8050.0000% mcap0.0% of flowCommon StockSEC:0001242914-26-000010:8
440 shares@ US$333.1770.0001% mcap0.1% of flowCommon StockSEC:0001242914-26-000010:9
200 shares@ US$333.9310.0001% mcap0.0% of flowCommon StockSEC:0001242914-26-000010:10
320 shares@ US$336.7930.0001% mcap0.0% of flowCommon StockSEC:0001242914-26-000010:12
11,257 shares@ US$338.8990.0031% mcap1.4% of flowCommon StockSEC:0001242914-26-000010:14
10,812 shares@ US$339.710.0030% mcap1.4% of flowCommon StockSEC:0001242914-26-000010:15
3,274 shares@ US$341.8390.0009% mcap0.4% of flowCommon StockSEC:0001242914-26-000010:17
805 shares@ US$343.4720.0002% mcap0.1% of flowCommon StockSEC:0001242914-26-000010:19
826 shares@ US$336.30270.0002% mcap100.0% of flowCommonSEC144:0001969223-26-000921
826 shares@ US$336.3040.0002% mcap61.4% of flowCommon StockSEC:0002055817-26-000004:0
350,000 shares@ US$335.00CommonSEC144:0001242914-26-000009
155 shares@ US$325.700.0000% mcap45.1% of flowCommon StockSEC:0002063975-26-000003:0
25 of 351 declarations
关于 STRYKER CORP
Stryker Corp.（股票代码：SYK）是美国一家领先的医疗保健公司，在纽约证券交易所上市。公司总部位于美国密歇根州波蒂奇，是医疗技术领域主要的全球参与者之一。其历史可追溯至 1941 年，当时 Homer Stryker 开始开发并商业化受其骨科实践启发的发明。这一渊源至今仍塑造着公司的特性：产品创新、与临床医生的紧密合作以及用于拓宽其产品组合的严谨收购策略。（[stryker.com](https://www.stryker.com/us/en/about.html?utm_source=openai)） Stryker 通过三个核心报告领域运营：医疗外科、神经技术和骨科。医疗外科包括手术设备、内窥镜、患者处理和患者安全技术以及精选的医院护理产品。神经技术涵盖神经外科和神经血管解决方案，以及某些脊柱和疼痛相关技术。骨科包括髋关节、膝关节、肩关节、创伤和四肢手术的植入物和解决方案。这种结构使 Stryker 在医院资本支出、择期手术和高价值专科手术方面实现了多元化布局。（[stryker.com](https://www.stryker.com/us/en/about.html?utm_source=openai)） 从竞争角度来看，Stryker 被广泛认为是顶级的医疗设备领导者，在医院和外科医生中拥有强大的品牌认知度。其定位建立在临床质量、强大的商业足迹以及提供结合器械、植入物、耗材和相邻数字解决方案的广泛手术平台的能力之上。公司拥有重要的全球业务，在美国、欧洲、中东和非洲、亚太地区以及包括加拿大和拉丁美洲在内的其他海外市场开展创收业务。（[sec.gov](https://www.sec.gov/Archives/edgar/data/310764/000031076425000023/syk-20241231.htm?utm_source=openai)） 其产品组合涵盖手术系统、医院设备、骨科植入物以及血栓切除术、血管内碎石术和足踝手术等新兴解决方案。近期公司发展突出表明其积极的并购议程以及持续向增长更快的血管类别推进：Stryker 于 2025 年 2 月完成了对 Inari Medical 的收购，随后利用该平台推出了 InThrill 和 Artix 等新产品。2026 年，它宣布并完成了对 Amplitude Vascular Systems 的收购，以加强其外周血管产品组合。公司还获得了 OptaBlate BVN 和 Incompass 等产品的 FDA 批准，凸显了其活跃的创新管线。（[investors.stryker.com](https://investors.stryker.com/press-releases/news-details/2025/Stryker-completes-acquisition-of-Inari-Medical-Inc.-providing-entry-into-the-high-growth-peripheral-vascular-segment/default.aspx?utm_source=openai)） 对于投资者而言，Stryker 仍然是美国高质量的医疗保健公司：具有防御性特征、持续创新、庞大的安装基础和持续的执行力。主要考虑因素是其对医院支出周期的敞口、激烈的竞争以及鉴于其技术驱动型业务的规模和复杂性所带来的运营或网络安全风险。（[globenewswire.com](https://www.globenewswire.com/news-release/2025/01/28/3016762/0/en/Stryker-reports-2024-operating-results-and-2025-outlook.html?utm_source=openai)）
